-
Product Insights
Retinal Pigment Epithelial (RPE) Detachment Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Retinal Pigment Epithelial (RPE) Detachment Global Clinical Trials Review, H2, 2018" provides an overview of Retinal Pigment Epithelial (RPE) Detachment clinical trials scenario. This report provides top line data relating to the clinical trials on Retinal Pigment Epithelial (RPE) Detachment. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Retinal Vein Occlusion Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Retinal Vein Occlusion Global Clinical Trials Review, H2, 2018" provides an overview of Retinal Vein Occlusion clinical trials scenario. This report provides top line data relating to the clinical trials on Retinal Vein Occlusion. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Retinitis Pigmentosa (Retinitis) Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Retinitis Pigmentosa (Retinitis) Global Clinical Trials Review, H2, 2018" provides an overview of Retinitis Pigmentosa (Retinitis) clinical trials scenario. This report provides top line data relating to the clinical trials on Retinitis Pigmentosa (Retinitis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Retinopathy Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Retinopathy Global Clinical Trials Review, H2, 2018" provides an overview of Retinopathy clinical trials scenario. This report provides top line data relating to the clinical trials on Retinopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Product Insights
Retinopathy Of Prematurity Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Retinopathy Of Prematurity Global Clinical Trials Review, H2, 2018" provides an overview of Retinopathy Of Prematurity clinical trials scenario. This report provides top line data relating to the clinical trials on Retinopathy Of Prematurity. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Rhino-Conjunctivitis Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Rhino-Conjunctivitis Global Clinical Trials Review, H2, 2018" provides an overview of Rhino-Conjunctivitis clinical trials scenario. This report provides top line data relating to the clinical trials on Rhino-Conjunctivitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Glaucoma: Competitive Landscape to 2026
Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye’s optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. In glaucoma patients, the IOP—the normal healthy eye pressure that is achieved when the eye produces a small amount of aqueous humor while letting an equal amount of fluid out of the eye—is disturbed due to mechanical compression and/or decreased blood flow to...
-
Sector Analysis
Age-Related Macular Degeneration: Competitive Landscape to 2026
Age-Related macular degeneration (AMD) is one of the leading cause of vision loss among people ages 50 and over in the developed world, characterized by the deterioration or breakdown of the macula, a small area of the central retina needed for sharp central vision, gradually diminishing central vision as a result in one or both eyes. This report provides an assessment of the pipeline, clinical, and commercial landscape of AMD. Overall, GlobalData expects that the approval of new vascular endothelial...
-
Product Insights
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Disease - Global Clinical Trials Review, H2 2019
GlobalData's clinical trial report, “Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Global Clinical Trials Review, H2, 2019" provides an overview of Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) clinical trials scenario. This report provides top line data relating to the clinical trials on Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country...
-
Sector Analysis
Retinal Vein Occlusion - Competitive Landscape in 2021
In RVO, Vascular Endothelial Growth Facto (VEGF) is a major focus of drug developers. There are 24 drugs in the pipeline with 80% molecules present in early stage. Mid-sized Pharma dominates R&D in this indication. The increasing prevalence and preference for branded therapies will drive the market's growth over the next six years, but the high cost of branded therapies is expected to limit their uptake.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.